Evidence map›Paper›PMID 29483219›Full record

ArticleMolecular cancer therapeutics2018

Targeting PRPK Function Blocks Colon Cancer Metastasis.

Tatyana Zykova, Feng Zhu, Lei Wang, Haitao Li, Do Young Lim, Ke Yao, Eunmiri Roh, Sang-Pil Yoon, Hong-Gyum Kim, Ki Beom Bae and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Biomolecules & biomedicine · 2024
    Article
  4. Article
  5. Article
  6. TP53RK Drives the Progression of Chronic Kidney Disease by Phosphorylating Birc5.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Tatyana Zykova *The Hormel Institute, University of Minnesota, Austin, Minnesota.
Feng Zhu *The Hormel Institute, University of Minnesota, Austin, Minnesota.
Lei Wang *The Hormel Institute, University of Minnesota, Austin, Minnesota.
Haitao Li *The Hormel Institute, University of Minnesota, Austin, Minnesota.
Do Young Lim *The Hormel Institute, University of Minnesota, Austin, Minnesota.
Ke Yao *The Hormel Institute, University of Minnesota, Austin, Minnesota.
Eunmiri RohThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Sang-Pil YoonThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Hong-Gyum KimThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Ki Beom BaeThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Weihong WenThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Seung Ho ShinThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Janos NadasThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Yan LiThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Weiya MaThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Ann M BodeThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Zigang DongThe Hormel Institute, University of Minnesota, Austin, Minnesota. zgdong@hi.umn.edu.
Jiangnan University · CN

Funding

Chemoprevention of colon cancer by targeting the Wnt/beta-catenin pathwayR01CA187027 · NCI · UNIVERSITY OF MINNESOTA · PI KANG, NINGLING, ROH, EUNMIRI · 2015 to 2019
$1.7M
Prevention of solar UV-induced skin cancer by targeting LTA4HR01CA196639 · NCI · UNIVERSITY OF MINNESOTA · PI LIU, LIANG · 2015 to 2019
$1.7M
Molecular Mechanisms and Targets of Soy Compounds in the Prevention of Colon CancR21CA172457 · NCI · UNIVERSITY OF MINNESOTA · PI DONG, ZIGANG · 2013 to 2014
$327k
NCI NIH HHS R01 CA187027NCI NIH HHS R01 CA196639NCI NIH HHS R21 CA172457
6 · The paper itself

Abstract

The biological functions of the p53-related protein kinase (PRPK) remain unclear. We have previously demonstrated that PRPK is phosphorylated by the T-LAK cell-originated protein kinase (TOPK) and that phosphorylated PRPK (p-PRPK) promotes colon cancer metastasis. Here, we analyzed colon adenocarcinomas from 87 patients and found that higher expression levels of p-PRPK were associated with later stages of metastatic dissemination (stage III and IV) as compared with earlier stages (stages I and II). Indeed, levels of p-PRPK were higher in metastatic versus malignant human colon adenocarcinomas. Knocking down PRPK expression attenuated colorectal liver and lung metastasis of colon cancer cells

Indexed as

AdenocarcinomaAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorColonic NeoplasmsFluorouracilFusidic AcidHCT116 CellsHT29 CellsHumansIntracellular Signaling Peptides and ProteinsLiver NeoplasmsLung NeoplasmsMiceMutationNeoplasms, ExperimentalBIRC5 protein, humanFluorouracilFusidic AcidIntracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesSurvivinTP53 protein, humanTP53RK protein, humanTumor Suppressor Protein p53

Identifiers

PMID29483219
PMCPMC5940014
OpenAlexW2792989524

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.